Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Canada Research Chairs

University of Victoria

$100,000.00

Microfluidics for drug discovery and healthcare

FY 2023-24

Summary
I propose to create a paradigm shift in the way that drugs are tested early in the discovery process by building artificial cells that mimic human cells. My research proposes a way to build bespoke artificial cells from the bottom up that contain the major membrane-based cellular components and organelles. We can use these systems to study both active and passive transport of drugs at the same time. This has the potential to create an exciting new direction in our fight against disease and cause ground-breaking advances in the medicinal sciences of the future. New drugs take 10-15 years to be developed and cost around US $2.6 billion each. Even at the later stages of the discovery process, there is a high failure rate since drug candidates can have unexpected effects when tested in humans. Overall, only ~14% of drugs gain regulatory approval, and there is increasing concern that animal studies do not accurately predict drug behaviour in the human body. In broad terms, the current paradigm for scientific research concerned with the biology underpinning diseases and the development of new drugs to cure them follows conventional steps. Initially in vitro studies are used, where drug candidates are tested using cell-free and then cell-based assays. This is followed by in vivo studies in animals, and finally clinical trials in humans. Alongside, from a medical perspective doctors study these diseases as they progress in humans. Over the last five years my research group have performed the fundamental research to develop a unique new method to quantify how molecules enter cells by building custom-made human-mimetic artificial cell membranes on a chip. Here, I will add the remaining membrane-based cellular components to my artificial cells. We will use these systems to perform fundamental studies into the effect that different membrane components have on drug passive membrane permeability. These include lipid domain formation, and the effect of disease and sex on permeability. Then, we will insert human uptake and efflux membrane transport proteins to be able to quantify active transport. Thirdly, since each compartment in a cell is delineated by a membrane, we will mimic these inside our droplet interface bilayer (DIB)-based artificial cells using liposomes. Finally, we will develop detection methods that allow us to quantify the kinetics of drug transport accurately in each location of the compartmentalised artificial cells.
Program
Canada Research Chairs
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
CRC-2021-00304
Name nom
Elvira, Katherine
Department département
Chemistry - University of Victoria
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2021
Award amount
100000
Program id
CRC
Program name en
Canada Research Chairs
Program name fr
Chaires de recherche du Canada
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
9998
Committee name en
Canada Research Chair Selection Committee
Committee name fr
Comité de sélection des Chaires de recherche du Canada
Area of application code
10000
Area of application group en
The socioeconomic objective available
Area of application group fr
L'objectif socioéconomique disponible
Area of application en
The socioeconomic objective available
Area of application fr
L'objectif socioéconomique disponible
Research subject code
10000
Research subject group en
The field of research available
Research subject group fr
The field of research available
Research subject en
Le domaine de recherche disponible
Research subject fr
Le domaine de recherche disponible
Field of research list codes
RDF1040199;RDF3010506
Field of research list names en
Analytical chemistry, n.e.c.;Drug discovery, design and delivery
Field of research list names fr
Chimie analytique, n.c.a.;Découverte, conception et administration de médicaments
Socioeconomic objective list codes
RDS10701
Socioeconomic objective list names en
Human health procedures and pharmaceutical treatments
Socioeconomic objective list names fr
Interventions et traitements pharmaceutiques ayant trait à la santé humaine
Application title
Microfluidics for drug discovery and healthcare
Keyword
Microfluidics; Drug discovery and development; Droplets; Artificial cells; Artificial tissues; Artificial cell membranes; Droplet interface bilayers (DIBs); Liposomes; Lab on a chip
Application summary
I propose to create a paradigm shift in the way that drugs are tested early in the discovery process by building artificial cells that mimic human cells. My research proposes a way to build bespoke artificial cells from the bottom up that contain the major membrane-based cellular components and organelles. We can use these systems to study both active and passive transport of drugs at the same time. This has the potential to create an exciting new direction in our fight against disease and cause ground-breaking advances in the medicinal sciences of the future. New drugs take 10-15 years to be developed and cost around US $2.6 billion each. Even at the later stages of the discovery process, there is a high failure rate since drug candidates can have unexpected effects when tested in humans. Overall, only ~14% of drugs gain regulatory approval, and there is increasing concern that animal studies do not accurately predict drug behaviour in the human body. In broad terms, the current paradigm for scientific research concerned with the biology underpinning diseases and the development of new drugs to cure them follows conventional steps. Initially in vitro studies are used, where drug candidates are tested using cell-free and then cell-based assays. This is followed by in vivo studies in animals, and finally clinical trials in humans. Alongside, from a medical perspective doctors study these diseases as they progress in humans. Over the last five years my research group have performed the fundamental research to develop a unique new method to quantify how molecules enter cells by building custom-made human-mimetic artificial cell membranes on a chip. Here, I will add the remaining membrane-based cellular components to my artificial cells. We will use these systems to perform fundamental studies into the effect that different membrane components have on drug passive membrane permeability. These include lipid domain formation, and the effect of disease and sex on permeability. Then, we will insert human uptake and efflux membrane transport proteins to be able to quantify active transport. Thirdly, since each compartment in a cell is delineated by a membrane, we will mimic these inside our droplet interface bilayer (DIB)-based artificial cells using liposomes. Finally, we will develop detection methods that allow us to quantify the kinetics of drug transport accurately in each location of the compartmentalised artificial cells.
University of Victoria - $100,000 Grant (2023-24) | Canada Spends